AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2231320 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release (ER) hydralazine once daily, daily doses of 75, 150, or 300 mg
Number of subjects: 181
Study 2231320 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant beta-blocker (BB) therapy
Number of subjects: 181
Study 2231320 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydralazine treatment
Number of subjects: 181
Study 112580 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorambucil maintenance
Number of subjects: 109
Study 112580 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxy-urea
Number of subjects: 109
Study 31481362 — intervention group
Group type: EXPERIMENTAL
Intervention: Music therapy (MT) focusing on parental singing tailored to infant responses during NICU and/or postdischarge 6-month period
Number of subjects: 250
Study 31481362 — intervention group
Group type: EXPERIMENTAL
Intervention: Music therapy (MT)
Number of subjects: 250
Study 31481362 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 250
Study 29947285 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginger aromatherapy (inhalation of essential oil of ginger)
Number of subjects: 49
Study 29947285 — intervention group
Group type: COMPARATOR
Intervention: Placebo (water)
Number of subjects: 49
Study 29947285 — intervention group
Group type: COMPARATOR
Intervention: Control (Johnson's baby shampoo)
Number of subjects: 49
Study 27816672 — intervention group
Group type: EXPERIMENTAL
Intervention: THS 2.2 (80 participants)
Number of subjects: 160
Study 27816672 — intervention group
Group type: COMPARATOR
Intervention: CC (41 participants)
Number of subjects: 160
Study 27816672 — intervention group
Group type: EXPERIMENTAL
Intervention: SA (39 participants)
Number of subjects: 160
Study 27816672 — intervention group
Group type: COMPARATOR
Intervention: THS 2.2 and CC (80 and 41 participants respectively)
Number of subjects: 160
Study 24268387 — intervention group
Group type: EXPERIMENTAL
Intervention: omega-3 (1 g, 3 times daily)
Number of subjects: 50
Study 24268387 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 50
Study 22902139 — intervention group
Group type: EXPERIMENTAL
Intervention: Instrument-assisted spinal manipulative therapy (SMT)
Number of subjects: 30
Study 22902139 — intervention group
Group type: COMPARATOR
Intervention: Sham manipulation procedure
Number of subjects: 30
Study 20230454 — intervention group
Group type: EXPERIMENTAL
Intervention: 240 mg lidocaine in 125 mL of saline once a week for 4 weeks
Number of subjects: 30
Study 20230454 — intervention group
Group type: COMPARATOR
Intervention: 25 mg amitriptyline
Number of subjects: 30
Study 18942422 — intervention group
Group type: COMPARATOR
Intervention: New Russian oral ribavirin-containing agents
Number of subjects: 0
Study 15675903 — intervention group
Group type: EXPERIMENTAL
Intervention: 90 seconds of CPR before defibrillation
Number of subjects: 256
Study 15675903 — intervention group
Group type: COMPARATOR
Intervention: Immediate defibrillation
Number of subjects: 256
Study 12352271 — intervention group
Group type: EXPERIMENTAL
Intervention: Nortriptyline
Number of subjects: 66
Study 12352271 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 66
Study 10329069 — intervention group
Group type: EXPERIMENTAL
Intervention: End-point committee evaluation of events
Number of subjects: 1209
Study 10329069 — intervention group
Group type: EXPERIMENTAL
Intervention: End-point committee evaluation
Number of subjects: 1209
Study 10329069 — intervention group
Group type: EXPERIMENTAL
Intervention: End-point committee judgements
Number of subjects: 1209
Study 7559165 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-filter model for frequency discrimination
Number of subjects: 3
Study 2082489 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (330 mg) and dipyridamole (75 mg) t.i.d.
Number of subjects: 0
Study 2082489 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 7436817 — intervention group
Group type: EXPERIMENTAL
Intervention: Sinemet 20/100 (20 mg of carbidopa to 100 mg of levodopa)
Number of subjects: 29
Study 7436817 — intervention group
Group type: COMPARATOR
Intervention: Sinemet 10/100 (10 mg of carbidopa to 100 mg of levodopa)
Number of subjects: 29
Study 7436817 — intervention group
Group type: COMPARATOR
Intervention: Levodopa alone (100 mg)
Number of subjects: 29
Study 31192423 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal occupational specific treatment for exhaustion disorder
Number of subjects: 0
Study 31192423 — intervention group
Group type: EXPERIMENTAL
Intervention: Reflective peer support group sessions
Number of subjects: 0
Study 28129020 — intervention group
Group type: EXPERIMENTAL
Intervention: Brinzolamide/Brimonidine Fixed Combination (BBFC) 1%/0.2% 3 times daily
Number of subjects: 60
Study 28129020 — intervention group
Group type: COMPARATOR
Intervention: Timolol maleate 0.5% twice daily
Number of subjects: 60
Study 25905534 — intervention group
Group type: EXPERIMENTAL
Intervention: Hot glutamate solution (48°C)
Number of subjects: 16
Study 25905534 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold glutamate solution (3°C)
Number of subjects: 16
Study 25905534 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline (neutral solution at 36°C)
Number of subjects: 16
Study 25905534 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold solutions
Number of subjects: 16
Study 22941095 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular exercise and counseling program for 6 months
Number of subjects: 1409
Study 22941095 — intervention group
Group type: COMPARATOR
Intervention: Control group (signal, mortar)
Number of subjects: 1409
Study 21343835 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose ZENPEP (7 × 5000 lipase units per day)
Number of subjects: 72
Study 21343835 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose ZENPEP (7 × 20,000 lipase units per day)
Number of subjects: 72
Study 21343835 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose ZENPEP (7 × 20,000 lipase units per day) in patients with baseline CFA < 90% (n = 33)
Number of subjects: 72
Study 21343835 — intervention group
Group type: EXPERIMENTAL
Intervention: Both doses of ZENPEP
Number of subjects: 72
Study 19462726 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior Tibial Nerve electrical stimulation (n=21)
Number of subjects: 37
Study 19462726 — intervention group
Group type: COMPARATOR
Intervention: Sham group (n=16)
Number of subjects: 37
Study 18611265 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariable model including four kallikrein forms (total, free, and intact PSA, and human kallikrein 2 (hK2))
Number of subjects: 740
Study 18611265 — intervention group
Group type: EXPERIMENTAL
Intervention: Threshold for biopsy set at 20% risk of prostate cancer
Number of subjects: 740
Study 15708868 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 150 microg (Cl-150)
Number of subjects: 0
Study 15708868 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 300 microg (Cl-300)
Number of subjects: 0
Study 15708868 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Cl-0)
Number of subjects: 0
Study 15708868 — intervention group
Group type: COMPARATOR
Intervention: ZEEP (zero end-expiratory pressure)
Number of subjects: 0
Study 12231079 — intervention group
Group type: EXPERIMENTAL
Intervention: DCA with stent (DCA-stent)
Number of subjects: 117
Study 12231079 — intervention group
Group type: COMPARATOR
Intervention: DCA only
Number of subjects: 117
Study 10223454 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantation of pre‐coincubated autologous adrenal medulla (AM) and intercostal nerve in the caudate nucleus.
Number of subjects: 8
Study 10223454 — intervention group
Group type: COMPARATOR
Intervention: Control group (nonsurgically treated patients).
Number of subjects: 8
Study 7633545 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-generated telephone reminder calls
Number of subjects: 517
Study 7633545 — intervention group
Group type: COMPARATOR
Intervention: No reminder calls (Control)
Number of subjects: 517
Study 7633545 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-generated telephone reminder calls (Immunization program)
Number of subjects: 517
Study 7633545 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-generated telephone reminder calls (Well-child program)
Number of subjects: 517
Study 7633545 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-generated telephone reminder calls (Women, infant, and children program)
Number of subjects: 517
Study 7633545 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-generated telephone reminder calls (Family-planning program)
Number of subjects: 517
Study 2568774 — intervention group
Group type: EXPERIMENTAL
Intervention: Iopromide
Number of subjects: 40
Study 2568774 — intervention group
Group type: COMPARATOR
Intervention: Iopamidol
Number of subjects: 40
Study 594788 — intervention group
Group type: EXPERIMENTAL
Intervention: Methyclothiazide 10 mg daily
Number of subjects: 120
Study 594788 — intervention group
Group type: COMPARATOR
Intervention: Methyclothiazide 5 mg daily
Number of subjects: 120
Study 594788 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 29739243 — intervention group
Group type: EXPERIMENTAL
Intervention: Suture closure
Number of subjects: 746
Study 29739243 — intervention group
Group type: COMPARATOR
Intervention: Staples
Number of subjects: 746
Study 27476326 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 weeks of training cessation
Number of subjects: 10
Study 25846053 — intervention group
Group type: EXPERIMENTAL
Intervention: Balance-training program provided by qualified care workers (QCWs) for 6 months
Number of subjects: 45
Study 25846053 — intervention group
Group type: EXPERIMENTAL
Intervention: Balance-training program provided by qualified care workers (QCWs)
Number of subjects: 45
Study 25846053 — intervention group
Group type: COMPARATOR
Intervention: Control group (no balance training)
Number of subjects: 45
Study 23398703 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual feedback system to alert operators of critical movements and to alert other workers in close proximity to the equipment.
Number of subjects: 0
Study 23398703 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual feedback system
Number of subjects: 0
Study 21309619 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined psycho- and pharmacotherapy for patients with co-morbid personality disorders (PDs)
Number of subjects: 562
Study 21309619 — intervention group
Group type: COMPARATOR
Intervention: Combined psycho- and pharmacotherapy for patients with no personality disorders (PDs)
Number of subjects: 562
Study 19167418 — intervention group
Group type: EXPERIMENTAL
Intervention: Heterozygous women
Number of subjects: 0
Study 19167418 — intervention group
Group type: COMPARATOR
Intervention: Age-matched controls
Number of subjects: 0
Study 16499796 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75% hyperbaric bupivacaine 1.5 ml with 0.25 ml fentanyl (12.5 microg)
Number of subjects: 60
Study 16499796 — intervention group
Group type: COMPARATOR
Intervention: 0.75% hyperbaric bupivacaine 1.5 ml with 0.25 ml normal saline
Number of subjects: 60
Study 14679137 — intervention group
Group type: EXPERIMENTAL
Intervention: Temozolomide 200 mg/m2/day
Number of subjects: 70
Study 14679137 — intervention group
Group type: EXPERIMENTAL
Intervention: Temozolomide 250 mg/m2/day
Number of subjects: 70
Study 14679137 — intervention group
Group type: EXPERIMENTAL
Intervention: Temozolomide 300 mg/m2/day
Number of subjects: 70
Study 14679137 — intervention group
Group type: EXPERIMENTAL
Intervention: Temozolomide 350 mg/m2/day
Number of subjects: 70
Study 14679137 — intervention group
Group type: EXPERIMENTAL
Intervention: Temozolomide 300 mg/m2/day recommended dose
Number of subjects: 70
Study 14679137 — intervention group
Group type: EXPERIMENTAL
Intervention: Temozolomide (dose-dense regimen)
Number of subjects: 70
Study 11704117 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (800 mg, three times per day for 10 days)
Number of subjects: 12
Study 11704117 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 9337922 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant radiotherapy
Number of subjects: 0
Study 8197841 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamma nail
Number of subjects: 378
Study 8197841 — intervention group
Group type: COMPARATOR
Intervention: Hip Compression Screw (HCS)
Number of subjects: 378
Study 3134518 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (beta-blocker)
Number of subjects: 12
Study 3134518 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive treatment (beta-blocker)
Number of subjects: 12
Study 3134518 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (450 kpm/min followed by 600 kpm/min)
Number of subjects: 12
Study 3134518 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 3134518 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term antihypertensive treatment
Number of subjects: 12
Study 30144146 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Oral Health Literacy (OHL) defined as BREALD-30 ≤ 21
Number of subjects: 344
Study 30144146 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Oral Health Literacy (OHL)
Number of subjects: 344
Study 30144146 — intervention group
Group type: COMPARATOR
Intervention: Higher Oral Health Literacy (OHL)
Number of subjects: 344
Study 28795232 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified hemi-split Doyle splint (Group 2)
Number of subjects: 64
Study 28795232 — intervention group
Group type: COMPARATOR
Intervention: Conventional Doyle intranasal silicone splint (Group 1)
Number of subjects: 64
Study 24580835 — intervention group
Group type: COMPARATOR
Intervention: Flap technique (control group)
Number of subjects: 34
Study 24580835 — intervention group
Group type: EXPERIMENTAL
Intervention: Flapless technique (test group)
Number of subjects: 34
Study 24002152 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical adapalene 0.1% gel
Number of subjects: 60
Study 24002152 — intervention group
Group type: COMPARATOR
Intervention: Topical benzoyl peroxide 2.5% gel
Number of subjects: 60
Study 21359582 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin-based treatment
Number of subjects: 1253
Study 21359582 — intervention group
Group type: COMPARATOR
Intervention: Insulin during hospitalisation followed by conventional glucose control (group 2)
Number of subjects: 1253
Study 21359582 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (group 3)
Number of subjects: 1253
Study 21359582 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 1253
Study 18191771 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial educational intervention (four 2-hour sessions focused on communication, stress appraisal, adaptive coping strategies, and building social support)
Number of subjects: 84
Study 18191771 — intervention group
Group type: COMPARATOR
Intervention: Supportive phone calls to PLWH alone (control group)
Number of subjects: 84
Study 17007184 — intervention group
Group type: EXPERIMENTAL
Intervention: Radical ethmoidectomy (nasalisation)
Number of subjects: 76
Study 17007184 — intervention group
Group type: COMPARATOR
Intervention: Functional ethmoidectomy
Number of subjects: 76
Study 14594526 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone 30 mg for 20 weeks
Number of subjects: 234
Study 14594526 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone 30 mg for 12 weeks followed by 45 mg for 8 weeks
Number of subjects: 234
Study 14594526 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone 45 mg for 20 weeks
Number of subjects: 234
Study 10918402 — intervention group
Group type: EXPERIMENTAL
Intervention: Foscarnet at dose level I (60/30 mg/kg/day)
Number of subjects: 20
Study 10918402 — intervention group
Group type: EXPERIMENTAL
Intervention: Foscarnet at dose level II (120/60 mg/kg/day)
Number of subjects: 20
Study 10918402 — intervention group
Group type: EXPERIMENTAL
Intervention: Foscarnet at dose level III (120/90 mg/kg/day)
Number of subjects: 20
Study 10918402 — intervention group
Group type: EXPERIMENTAL
Intervention: Foscarnet at dose level IV (120/120 mg/kg/day)
Number of subjects: 20
Study 10918402 — intervention group
Group type: EXPERIMENTAL
Intervention: Foscarnet at dose levels I and II
Number of subjects: 20
Study 10918402 — intervention group
Group type: EXPERIMENTAL
Intervention: Foscarnet at dose levels III and IV
Number of subjects: 20
Study 10918402 — intervention group
Group type: EXPERIMENTAL
Intervention: Foscarnet at dose levels I-II
Number of subjects: 20
Study 10918402 — intervention group
Group type: EXPERIMENTAL
Intervention: Foscarnet at dose levels III-IV
Number of subjects: 20
Study 10918402 — intervention group
Group type: EXPERIMENTAL
Intervention: Foscarnet (all dose levels)
Number of subjects: 20
Study 9013007 — intervention group
Group type: EXPERIMENTAL
Intervention: Duplex surveillance
Number of subjects: 100
Study 9013007 — intervention group
Group type: COMPARATOR
Intervention: Clinical follow-up
Number of subjects: 100
Study 1395658 — intervention group
Group type: EXPERIMENTAL
Intervention: Acidified enteral feedings (pH 3.5)
Number of subjects: 23
Study 1395658 — intervention group
Group type: COMPARATOR
Intervention: Regular feedings into the stomach (pH 4.7)
Number of subjects: 23
Study 1395658 — intervention group
Group type: COMPARATOR
Intervention: Regular feedings into the duodenum (pH 3.8)
Number of subjects: 23
Study 3911735 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg hydrochlorothiazide plus 5 mg amiloride (HCTZ/A)
Number of subjects: 18
Study 3911735 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg hydrochlorothiazide plus 26 mmol potassium chloride (HCTZ/K)
Number of subjects: 18
Study 3911735 — intervention group
Group type: EXPERIMENTAL
Intervention: HCTZ/K (double dose: 100 mg/52 mmol)
Number of subjects: 18
Study 3911735 — intervention group
Group type: EXPERIMENTAL
Intervention: HCTZ/A (double dose: 100 mg/10 mg)
Number of subjects: 18
Study 3911735 — intervention group
Group type: EXPERIMENTAL
Intervention: Both drug combinations
Number of subjects: 18
Study 3911735 — intervention group
Group type: COMPARATOR
Intervention: HCTZ/A
Number of subjects: 18
Study 28318688 — intervention group
Group type: EXPERIMENTAL
Intervention: PKU type meal
Number of subjects: 23
Study 28318688 — intervention group
Group type: COMPARATOR
Intervention: Control meal (ordinary meal and protein-enriched milk)
Number of subjects: 23
Study 27707828 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care + enhanced rehabilitation package (including six additional home-based physiotherapy sessions, novel information workbook, and goal-setting diary)
Number of subjects: 62
Study 27707828 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 62
Study 27707828 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care + enhanced rehabilitation package
Number of subjects: 62
Study 25001475 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted temperature management at 33 °C (TTM33; n = 71)
Number of subjects: 139
Study 25001475 — intervention group
Group type: COMPARATOR
Intervention: Targeted temperature management at 36 °C (TTM36; n = 68)
Number of subjects: 139
Study 25001475 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted temperature management at 33 °C (TTM33)
Number of subjects: 139
Study 25001475 — intervention group
Group type: COMPARATOR
Intervention: Targeted temperature management at 36 °C (TTM36)
Number of subjects: 139
Study 22515908 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% EDTA
Number of subjects: 25
Study 22515908 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% EDTA + 0.25% cetrimide
Number of subjects: 25
Study 22515908 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% EDTA + 0.50% cetrimide
Number of subjects: 25
Study 22515908 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% cetrimide
Number of subjects: 25
Study 22515908 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.50% cetrimide
Number of subjects: 25
Study 21207919 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% potassium nitrate dentifrice
Number of subjects: 30
Study 21207919 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% NovaMin dentifrice
Number of subjects: 30
Study 21207919 — intervention group
Group type: COMPARATOR
Intervention: Non-desensitizing dentifrice
Number of subjects: 30
Study 18504760 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadobutrol (1.0 mmol Gd/mL, 15 mL)
Number of subjects: 52
Study 18504760 — intervention group
Group type: COMPARATOR
Intervention: Gadoterate (0.5 mmol Gd/mL, 30 mL)
Number of subjects: 52
Study 15995262 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-leg heel raises
Number of subjects: 16
Study 15995262 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-leg heel raises
Number of subjects: 16
Study 15995262 — intervention group
Group type: COMPARATOR
Intervention: External resistance (+5% of body weight)
Number of subjects: 16
Study 15995262 — intervention group
Group type: COMPARATOR
Intervention: External resistance (+10% of body weight)
Number of subjects: 16
Study 15995262 — intervention group
Group type: COMPARATOR
Intervention: No external resistance
Number of subjects: 16
Study 14560166 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducational parenting program (3 weekly sessions + 1-month booster)
Number of subjects: 222
Study 14560166 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 222
Study 10788201 — intervention group
Group type: EXPERIMENTAL
Intervention: Students for Peace intervention (multi-component violence-prevention program)
Number of subjects: 2246
Study 10788201 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 2246
Study 8898462 — intervention group
Group type: EXPERIMENTAL
Intervention: Praziquantel (40 mg/kg body weight)
Number of subjects: 436
Study 8898462 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 436
Study 1716644 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone (100 mg PO)
Number of subjects: 6
Study 1716644 — intervention group
Group type: COMPARATOR
Intervention: Control (Org 10172 IV bolus injection of 3250 anti‐Xa units)
Number of subjects: 6
Study 6348123 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetracycline HCl (1 gm/day for 14 days)
Number of subjects: 21
Study 6348123 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 31302899 — intervention group
Group type: EXPERIMENTAL
Intervention: Erenumab
Number of subjects: 0
Study 31302899 — intervention group
Group type: COMPARATOR
Intervention: OnabotulinumtoxinA
Number of subjects: 0